Clinical Trials Logo

Gastrointestinal Function clinical trials

View clinical trials related to Gastrointestinal Function.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06368713 Recruiting - Quality of Life Clinical Trials

Exercise Improves Gastrointestinal Function in Peritoneal Dialysis Patients

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This study will investigate the impact of exercise on gastrointestinal function in peritoneal dialysis patients.

NCT ID: NCT06254716 Recruiting - Quality of Life Clinical Trials

A Study on the Prognosis of Two Different Surgery Methods in Patients With Rectal Endometriosis

Start date: January 1, 2024
Phase:
Study type: Observational

This retrospective study aims to compare the surgical and pregnancy outcomes of disc and segmental resection for rectal DIE through a single-center retrospective analysis, to summarize clinical experience, and to explore the possible factor of the differences. The results would provide preliminary clinical basis for the treatment and selection of surgical methods for patients with rectal DIE, and also provide a research basis for the prospective clinical studies.

NCT ID: NCT03291574 Recruiting - Acupuncture Clinical Trials

Perioperative Electroacupuncture for Gastric Cancer Patients After Gastrectomy

Start date: July 29, 2017
Phase: N/A
Study type: Interventional

Evaluate the effect of Perioperative Electroacupuncture on rapid rehabilitation for the gastric cancer patients after gastrectomy .

NCT ID: NCT03291561 Recruiting - Acupuncture Clinical Trials

Perioperative Electroacupuncture After Operation

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Evaluate the effect of perioperative electroacupuncture on rapid rehabilitation for the pancreatic cancer and periampullary carcinoma patients after operation .

NCT ID: NCT01542970 Recruiting - Allergy Clinical Trials

Can Supplementation With Lactobacillus Reuteri and Omega-3 Fatty Acids During Pregnancy and Lactation Reduce the Risk of Allergic Disease in Infancy?

PROOM-3
Start date: February 2012
Phase: N/A
Study type: Interventional

The incidence of allergic disease has increased worldwide during the last decades. Initially, a lot of effort has been put in elucidating which of the known risk factors commonly associated to the development of allergic disease early in life was the cause of this increase. Studies showing a reduced incidence of allergic disease in the former socialist countries in comparison to countries with a "Western lifestyle" have shown that risk factors as allergen exposure, environmental pollution and tobacco exposure are also present in societies with a less affluent lifestyle. This suggests the disappearance of factor protecting against the development of allergic diseases in affluent environment.The development of allergic diseases begins during the first year of life with eczema, both non-IgE- and IgE-associated, and food allergy, progressing during childhood with the development of asthma bronchiale, also both non-IgE- and IgE-associated, and later development of allergic rhinoconjunctivitis, i.e. the atopic march. The immune system of the neonate is influenced by maternal immunity, both via the placenta and breast milk. Thus, the immunological interaction between the mother and her offspring is close during pregnancy and lactation. The association of cord blood IgE levels with maternal but not paternal atopic heredity, may depend on a possibly stronger placental Th2 shift in atopic mothers. Thus, factors influencing/protecting against the development of allergic disease early in life, would be important already during pregnancy, birth and early postnatal life. Two major hypotheses have been assessed during the last decade: Proper microbial stimulation, including the establishment of the gut flora in infancy and the relationship between low omega 3-polyunsaturated fatty acids in the western diet and the incidence of allergic disease. This is a double blind randomized study. Families with at least one parent/sibling with clinical symptoms/history of allergic disease will be invited to participate in this study. Pregnant mothers will be included in the study at the 20th week of gestation. They will be randomized to 4 study groups, one will receive placebo capsules, the second will receive omega-3 PUFA supplementation and placebo regarding L. reuteri, the third will receive L. reuteri and placebo regarding omega-3 PUFA and the fourth group will receive both omega-3 PUFA and L. reuteri supplementation. Omega-3 supplementation will be given to mothers from pregnancy and lactation while L. reuteri will be given to the mothers during pregnancy and later to the children during the first year of life.The children will be clinically followed by an allergy nurse regularly. Questionnaires regarding data on environment, siblings, pets, breast feeding, smoking exposure, upper respiratory and other infections and clinical symptoms of allergic disease will be filled regularly. Skin prick tests (SPTs) will be performed in the children at 6 and 12 months with milk, egg, wheat, peanut and cat. At 24 months, timothy and birch allergen extracts will be added. A pediatrician will assess the children at 24 months of life and whenever it is needed during the study period. Dietary habits will be assessed during pregnancy (25th gestational week) and 6 months after child birth. Blood samples in the children will be taken from cord blood and at 6, 12 and 24 months of life. Maternal blood samples will be taken at 20th weeks of gestation and at child birth. Milk samples will be collected 1-4 days after partus and monthly during the first 4 months of lactation. Maternal gastrointestinal function will be addressed by validated diary cards. Saliva from the children and fecal samples from mother and child will also be collected according to the following protocol.